UBS Group
ACHV icon

UBS Group’s Achieve Life Sciences ACHV Stock Holding History

UBS Group’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$959K Buy
326,270
+41,041
+14% +$182K ﹤0.01% 5588
2025
Q4 		$1.42M Buy
285,229
+206,087
+260% +$898K ﹤0.01% 5271
2025
Q3 		$249K Sell
79,142
-5,772
-7% -$15.8K ﹤0.01% 6540
2025
Q2 		$192K Buy
84,914
+18,822
+28% +$53.6K ﹤0.01% 6752
2025
Q1 		$176K Buy
66,092
+13,750
+26% +$42.8K ﹤0.01% 6631
2024
Q4 		$184K Buy
52,342
+36,104
+222% +$164K ﹤0.01% 6497
2024
Q3 		$77K Buy
16,238
+5,788
+55% +$26.4K ﹤0.01% 6541
2024
Q2 		$49.1K Buy
10,450
+10,448
+522,400% +$50.3K ﹤0.01% 6703
2024
Q1 		$9 Hold
2
– – ﹤0.01% 9109
2023
Q4 		$8 Sell
2
-1,257
-100% -$5.47K ﹤0.01% 9128
2023
Q3 		$5.41K Buy
1,259
+1,093
+658% +$5.51K ﹤0.01% 7371
2023
Q2 		$862 Sell
166
-560
-77% -$3.93K ﹤0.01% 8076
2023
Q1 		$4.94K Buy
+726
New +$3.45K ﹤0.01% 8116
2022
Q3 		– Sell
-1,077
Closed -$5K – 10263
2022
Q2 		$5K Buy
+1,077
New +$7.3K ﹤0.01% 8840
2022
Q1 		– Sell
-80
Closed -$1K – 10164
2021
Q4 		$1K Hold
80
– – ﹤0.01% 9941
2021
Q3 		$1K Sell
80
-509
-86% -$3.99K ﹤0.01% 9128
2021
Q2 		$6K Buy
+589
New +$5.61K ﹤0.01% 8420
2021
Q1 		– Sell
-5,064
Closed -$41K – 8919
2020
Q4 		$41K Buy
5,064
+3,038
+150% +$25.7K ﹤0.01% 6352
2020
Q3 		$17K Sell
2,026
-2,571
-56% -$23.6K ﹤0.01% 6432
2020
Q2 		$37K Buy
4,597
+667
+17% +$5.32K ﹤0.01% 6113
2020
Q1 		$26K Buy
3,930
+3,164
+413% +$30.6K ﹤0.01% 6317
2019
Q4 		$8K Buy
766
+603
+370% +$12.9K ﹤0.01% 7377
2019
Q3 		$6K Buy
+163
New +$6.41K ﹤0.01% 7386
2019
Q2 		– Hold
0
– – – 7821
2019
Q1 		– Sell
-49
Closed -$1.98K – 7680
2018
Q4 		$1K Sell
49
-300
-86% -$11.3K ﹤0.01% 7872
2018
Q3 		$22K Buy
+349
New +$22.1K ﹤0.01% 6744
2018
Q2 		– Sell
-41
Closed -$10K – 7936
2018
Q1 		$10K Buy
41
+39
+1,950% +$11.2K ﹤0.01% 6845
2017
Q4 		$1K Sell
2
-11
-85% -$3.52K ﹤0.01% 7686
2017
Q3 		$5K Buy
+13
New +$9.33K ﹤0.01% 7200
2017
Q2 		– Sell
-34
Closed -$33K – 7614
2017
Q1 		$33K Buy
+34
New +$41.3K ﹤0.01% 5776
2016
Q4 		– Sell
-39
Closed -$43K – 7740
2016
Q3 		$43K Buy
39
+34
+680% +$54.2K ﹤0.01% 5630
2016
Q2 		$10K Buy
5
+3
+150% +$6.26K ﹤0.01% 6773
2016
Q1 		$3K Sell
2
-6
-75% -$9.78K ﹤0.01% 7172
2015
Q4 		$21K Buy
8
+1
+14% +$4.23K ﹤0.01% 6699
2015
Q3 		$35K Buy
7
+6
+600% +$36.1K ﹤0.01% 6134
2015
Q2 		$3K Buy
+1
New +$4.96K ﹤0.01% 8049
2015
Q1 		– Sell
-1
Closed -$4.91K – 8719
2014
Q4 		$5K Buy
+1
New +$4.89K ﹤0.01% 8940

Other funds holding ACHV

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's ACHV Position: Q1 2026 in Review

UBS Group increased its Achieve Life Sciences (ACHV) stake by 14% in Q1 2026, buying an estimated $182K and bringing the position to 326,270 shares worth $959K. The position accounts for ﹤0.01% of the portfolio, ranked #5588.

UBS Group first reported a position in ACHV in Q4 2014 and has held it in 36 quarters since. The position peaked at $1.42M in Q4 2025. 81 funds tracked by Wall St. Rank hold ACHV as of Q1 2026.

  • UBS Group held 326,270 shares of Achieve Life Sciences worth $959K as of Q1 2026.
  • UBS Group bought 41,041 Achieve Life Sciences shares in Q1 2026, an estimated $182K.
  • Achieve Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5588 holding.
  • UBS Group first reported a position in Achieve Life Sciences in Q4 2014 and has held it in 36 quarters since.
  • UBS Group's Achieve Life Sciences position peaked at $1.42M in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.